Following the release of the Final Draft Guidance, NHS England submitted a request to vary the funding requirement timeframe for implementation of the committee recommendation. The NICE Guidance Executive has reviewed the application and are minded to agree to the variation request. Please see section 5.9.25 – 5.9.34 of the Health Technology Evaluation guidance development manual for more information on variations to the funding requirement.
Stakeholders have been asked to comment on the proposal set out in the funding variation document for extending the statutory period for funding nirmatrelvir plus ritonavir in the broader population. The request to vary the funding requirement timeframe has published on the NICE website for information only.
This page was last updated: